Michaela Bazo

Michaela Bazo, CEO of Metanova, is at the forefront of revolutionizing drug discovery with the first decentralized screening platform on Bittensor. She discusses how Metanova leverages an AI-driven network to screen millions of molecules more efficiently and affordably. The conversation dives into targeting behavioral drugs, the impact of decentralization on R&D, and potential big pharma partnerships. Michaela also reveals plans for wet lab validation and the transition to a token-based revenue model, highlighting a promising future for biotech innovation.